Business Context and Reporting Period
CVRx, Inc. (CVRX) is a commercial-stage medical device company focused on the Barostim neuromodulation system for heart failure (HFrEF) and resistant hypertension. This Form 10-Q covers the quarterly period ended June 30, 2025. The company operates as a single reporting segment with revenue derived primarily from the U.S. and Europe. As of July 29, 2025, there were 26,151,724 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $13.6 million | $25.9 million |
| Gross Profit | $11.5 million | $21.8 million |
| Gross Margin | 84% | 84% |
| Net Loss | $(14.7) million | $(28.5) million |
| Net Loss Per Share (Basic/Diluted) | $(0.57) | $(1.10) |
| Cash and Cash Equivalents | $95.0 million (as of June 30, 2025) | N/A |
| Long-Term Debt | $49.4 million | N/A |
| Operating Cash Flow | N/A | $(20.7) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year (YoY) for both the three and six-month periods, driven by a 15% increase in U.S. sales and a 19-20% increase in European sales.
- Unit Volume: U.S. HF revenue units increased to 387 in Q2 2025 (from 339 in Q2 2024) and 740 for the six months (from 658). Active implanting centers in the U.S. grew to 240 from 189.
- Expense Management:
- Q2: SG&A expenses increased 11% YoY due to higher compensation and travel costs, while R&D decreased 11%.
- YTD: SG&A expenses decreased 10% YoY, primarily due to an $8.2 million reduction in non-cash stock-based compensation (excluding a one-time $8.4 million expense in Q1 2024 related to a former CEO's retirement). R&D expenses decreased 14% YoY.
- Interest Expense: Increased 54% in Q2 and 53% YTD due to higher borrowings under the Innovatus Loan Agreement.
- Liquidity: Cash balances decreased from $105.9 million at year-end 2024 to $95.0 million at June 30, 2025, reflecting operating losses partially offset by financing activities.
Guidance, Outlook, and Risks
- Reimbursement Outlook: In July 2025, CMS released the 2026 Proposed Medicare Physician Fee Schedule, establishing new Category I CPT codes for Barostim. This is expected to eliminate automatic denials and improve prior authorization predictability, effective January 1, 2026. CMS also proposed retaining the procedure under New Technology APC 1580 with a payment rate of approximately $45,000.
- Capital Resources: Management believes existing cash resources and cash from operations will be sufficient for at least the next three years. The company has $50.0 million in outstanding term loans (interest-only through Nov 2027) and $6.7 million remaining capacity under its At-The-Market (ATM) equity offering program.
- Risks:
- History of significant losses with no assurance of future profitability.
- Dependence on a single product (Barostim) and limited commercial sales experience.
- Reliance on third-party payers for adequate coverage and reimbursement.
- Regulatory compliance risks in the EU (MDR) and potential supply chain disruptions.
- Unusual Items: The YTD decrease in SG&A was significantly influenced by the absence of the $8.4 million non-cash stock-based compensation expense recognized in the prior year period related to the modification of the former CEO's stock options.
Investor Verification Checklist
- Verify the finalization and effective date of the 2026 CMS Category I CPT codes and the associated $45,000 APC payment rate.
- Monitor the trajectory of U.S. active implanting centers and unit volume growth to assess commercialization momentum.
- Review the company's cash burn rate relative to its $95 million cash balance and $50 million debt obligation to confirm the three-year liquidity runway.
- Assess the impact of the Innovatus Loan Agreement covenants, specifically the revenue target requirements, on future financing flexibility.
- Track the utilization of the remaining $6.7 million ATM offering capacity and potential dilution from future equity raises.